Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Immuno-Grade Somatostatin Receptor 5 Antibody

Close filters
No results were found for the filter!
Citations
KO-Validated
Immunohistochemical identification of Somatostatin Receptor 5 in human pancreatic islets
SST5 (IHC-grade), Somatostatin Receptor 5 Antibody
The SST5 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Somatostatin Receptor 5. In can be used to detect total SST5 receptors in Western blots independent of phosphorylation. The SST5...
$ 350.00 *
Details

The somatostatin receptor 5 (SST5) is the primary target for pasireotide (Signifor) which is the first line medical treatment for adrenocorticotropic hormone (ACTH)-producing adenomas (Cushing’s disease). The SST5 receptor is abundantly localized at the plasma membrane of a variety of normal tissues including anterior pituitary, pancreatic islets, enterochromaffine cells throughout the gut. SST5 is highly expressed in many neuroendocrine tumors including pituitary adenoma and carcinoid. SST5 immunohistochemistry predicts response to pasireotide.

The somatostatin receptor 5 (SST5) is the primary target for pasireotide (Signifor) which is the first line medical treatment for adrenocorticotropic hormone (ACTH)-producing adenomas (Cushing’s... read more »
Close window
Immuno-Grade Somatostatin Receptor 5 Antibody

The somatostatin receptor 5 (SST5) is the primary target for pasireotide (Signifor) which is the first line medical treatment for adrenocorticotropic hormone (ACTH)-producing adenomas (Cushing’s disease). The SST5 receptor is abundantly localized at the plasma membrane of a variety of normal tissues including anterior pituitary, pancreatic islets, enterochromaffine cells throughout the gut. SST5 is highly expressed in many neuroendocrine tumors including pituitary adenoma and carcinoid. SST5 immunohistochemistry predicts response to pasireotide.

Recently viewed